FTRE

FortreaA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$20.00

+28.0% vs current

Most likely

Base case

45%

Probability

Target price

$14.80

-5.3% vs current

B-

Bear case

30%

Probability

Target price

$10.00

-36.0% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Primary-source evidence turned better after the May 5, 2026 print, but this still looks like a monitoring setup rather than a clean bullish rerating. The earnings release and IR deck showed an earnings beat, affirmed guidance, and better bookings, while delayed analyst reaction on May 6 included target increases from Citi and Barclays. Secondary price-history sources indicate a sharp positive move on the earnings date, but exact post-print price action was not independently primary-verified here. Counterbalancing that, analyst coverage is thin, consensus targets remain around or slightly below the May 7 anchor price, and the company still has to prove revenue conversion, cash-flow improvement, and deleveraging.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-06eventRecovery in functional service provider demand and backlog conversionHigh impact

The 10-Q said Q1 organic revenue fell 3.2% because of lower pass-through costs and lower demand in the functional service provider business, partly offset by higher full-service revenue from net new business; evidence that FSP demand stabilizes and backlog converts without cancellations would improve confidence in the growth recovery [#10-Q-2026-05-05].

2026-08-06catalystQ1 earnings reset needs a second proof point on bookings and cost takeoutHigh impact

Fortrea reported Q1 revenue of $636.5 million, adjusted EBITDA of $47.0 million, adjusted EPS of $0.16, a 1.15x quarterly book-to-bill, and affirmed full-year 2026 guidance; the next decision point is whether bookings stay above replacement levels and cost optimization remains on track rather than Q1 being a one-quarter rebound [#8-K-2026-05-05] [#IR-2026-05-05].

2026-12-31catalystFY2026 margin expansion and deleveraging executionHigh impact

Management said it is on track for $70-80 million of gross and $40-50 million of net 2026 cost optimization, while Q1 net leverage was 4.4x, free cash flow was negative, and gross debt remained above $1.0 billion; sustained margin improvement with better cash generation is the main medium-term rerating path [#10-Q-2026-05-05] [#IR-2026-05-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology